Privi Speciality Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.7 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Privi Speciality Chemicals reported strong Q1 FY26 results, with standalone revenue from operations rising to Rs. 56,635.59 lakhs from Rs. 44,116.43 lakhs in Q1 FY25, a growth of about 28%. Standalone net profit jumped to Rs. 6,819.15 lakhs from Rs. 3,213.97 lakhs, more than doubling year-on-year. Consolidated revenue grew roughly 20% to Rs. 55,881.24 lakhs, while consolidated net profit attributable to owners rose to Rs. 5,707.92 lakhs from Rs. 3,145.35 lakhs, up about 82%. Standalone EPS came in at Rs. 17.58 versus Rs. 8.25, and consolidated EPS at Rs. 15.85 versus Rs. 9.05. Statutory auditors BSR & Co. LLP issued an unmodified limited review conclusion on both sets of results. The company operates in a single segment, Aroma Chemicals, and results include wholly owned subsidiaries Privi Biotechnologies, Privi Speciality Chemicals USA Corporation, and subsidiary Prigiv Specialties.
Strong topline growth of over 20% combined with a sharp jump in profitability signals improving demand and operating leverage, which is positive for shareholders. The clean auditor report and absence of any flagged concerns support a constructive near-term stock view.